Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Limited has cancelled 849,070 fully paid ordinary shares following an on‑market buy-back completed on 19 December 2025. The reduction in issued capital through this buy-back is likely to enhance capital management efficiency and may be marginally accretive to remaining shareholders, reflecting the company’s active approach to optimising its balance sheet and shareholder structure.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the medical diagnostics and pathology services industry, providing laboratory testing and related clinical services across Australia. The company’s operations support healthcare providers and patients through a broad range of diagnostic tests, positioning it as a key player in the national pathology and clinical laboratory market.
Average Trading Volume: 735,072
Technical Sentiment Signal: Hold
Current Market Cap: A$525.7M
See more data about ACL stock on TipRanks’ Stock Analysis page.